Physician profile
Betsy S Cramer
NPI 1003656281
$1,893.79
in general payments reported to CMS, 2019-2025
23 companies · $1,598 in 2025
The $1,598 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $296 · 2025: $1,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.84 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $271.95 | 2024-2025 | Airsupra, Farxiga, Tezspire |
| Otsuka America Pharmaceutical, INC. | $190.37 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.52 | 2024-2025 | Caplyta |
| Viatris Specialty LLC | $174.82 | 2025 | Yupelri |
| Amgen INC. | $102.00 | 2024-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $99.91 | 2024-2025 | Dupixent |
| Lundbeck LLC | $97.75 | 2024-2025 | Rexulti |
| Abbvie INC. | $97.46 | 2024-2025 | |
| Corcept Therapeutics | $74.85 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $65.55 | 2025 | Fanapt |
| Genzyme Corporation | $62.93 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.84 | 2024-2025 | |
| Novo Nordisk INC | $48.99 | 2025 | Wegovy, Ozempic |
| Mylan Specialty L.P. | $47.65 | 2024 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $46.65 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $32.97 | 2025 | Xolair |
| Verona Pharma, INC. | $30.65 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $29.23 | 2025 | Nuzyra, Xhance |
| Alkermes, INC. | $28.08 | 2025 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $26.07 | 2024 | |
| Lilly USA, LLC | $19.50 | 2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $15.10 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.